

Board of Governors of the Federal Reserve System, August 11, 1993.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 93-19883 Filed 8-17-93; 8:45 am]

BILLING CODE 6210-01-F

The Poca Valley Bankshares, Inc., et al.; Formations of; Acquisitions by; and Mergers of Bank Holding Companies

The companies listed in this notice have applied for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) and § 225.14 of the Board's Regulation Y (12 CFR 225.14) to become a bank holding company or to acquire a bank or bank holding company. The factors that are considered in acting on the applications are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Unless otherwise noted, comments regarding each of these applications must be received not later than September 10, 1993.

A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. *The Poca Valley Bankshares, Inc.*, Walton, West Virginia; to become a bank holding company by acquiring 100 percent of the voting shares of The Poca Valley Bank, Walton, West Virginia.

B. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *First Delta Corporation*, Helena, Arkansas; to acquire at least 75.25 percent of the voting shares of The Delta State Bank, Elaine, Arkansas.

C. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Watford City Bancshares, Inc.*, Watford City, North Dakota; to merge with Fessenden Bancshares, Inc.,

Fessenden, North Dakota, and thereby indirectly acquire First International Bank and Trust, N.A., Fessenden, North Dakota.

D. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Robert Lee Bancshares, Inc.*, Robert Lee, Texas; to become a bank holding company by acquiring 100 percent of the voting shares of Robert Lee (Delaware), Inc., Wilmington, Delaware, and thereby indirectly acquire Robert Lee State Bank, Robert Lee, Texas. In connection with this application, Robert Lee (Delaware), Inc., Wilmington, Delaware, has applied to become a bank holding company by acquiring 93.61 percent of the voting shares of Robert Lee State Bank, Robert Lee, Texas.

Board of Governors of the Federal Reserve System, August 11, 1993.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 93-19884 Filed 8-17-93; 8:45 am]

BILLING CODE 6210-01-F

Public Finance Service, Inc.; Formation of, Acquisition by, or Merger of Bank Holding Companies; and Acquisition of Nonbanking Company

The company listed in this notice has applied under § 225.14 of the Board's Regulation Y (12 CFR 225.14) for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) to become a bank holding company or to acquire voting securities of a bank or bank holding company. The listed company has also applied under § 225.23(a)(2) of Regulation Y (12 CFR 225.23(a)(2)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies, or to engage in such an activity. Unless otherwise noted, these activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as

greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 10, 1993.

A. Federal Reserve Bank of Philadelphia (Thomas K. Desch, Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. *Public Finance Service, Inc.*, Bala Cynwyd, Pennsylvania; to become a bank holding company by acquiring 100 percent of the voting shares of Public Savings Association, Bala Cynwyd, Pennsylvania. Public Savings Association will convert to a Pennsylvania savings bank and will operate under the name Public Savings Bank.

In connection with this application, Applicant also proposes to acquire Public Consumer Discount Company, Inc., Bala Cynwyd, Pennsylvania, and thereby engage in making and collecting consumer finance loans pursuant to § 225.25(b)(1)(i) of the Board's Regulation Y. These activities will be conducted throughout the State of Pennsylvania.

Board of Governors of the Federal Reserve System, August 11, 1993.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 93-19885 Filed 8-17-93; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Variability of Respiratory Trace Deposition in Workers: Meeting

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Variability of Respiratory Trace Deposition in Workers.

Time and Date: 8:30 a.m.-2:30 p.m.,
September 21, 1993.

Place: Appalachian Laboratory, room 138,
944 Chestnut Ridge Road, Morgantown, West
Virginia 26505-2888.

Status: Open to the public, limited only by
the space available.

Purpose: The purpose of the meeting is to
review the project entitled, "Variability of
Respiratory Tract Deposition in Workers."
Viewpoints and suggestions from industry,
labor, academic, other government agencies,
and the public are invited.

Contact Person for Additional Information:
Lu-Ann F. Beeckman, Ph.D., NIOSH, CDC,
944 Chestnut Ridge Road, Mailstop 240,
Morgantown, West Virginia 26505-2888,
telephone 304/291-4223.

Dated August 11, 1993.

Elvin Hilyer

*Associate Director for Policy Coordination
Centers for Disease Control and Prevention
(CDC).*

[FR Doc. 93-19936 Filed 8-17-93; 8:45 am]
BILLING CODE 4160-19-M

Food and Drug Administration

[Docket No. 93F-0243]

BASF Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing
that BASF Corp. has filed a petition
proposing that the food additive
regulations be amended to provide for
the safe use of 4,5,6,7-tetrachloro-2-[2-
(4,5,6,7-tetrachloro-2,3-dihydro-1,3-
dioxo-1H-inden-2-yl)-8-quinolinyl]-1H-
isoindole-1,3(2H)-dione (C.I. Pigment
Yellow 138), as a colorant in all food-
contact polymers.

DATES: Written comments on
petitioner's environmental assessment
by September 17, 1993.

ADDRESSES: Submit written comments
to the Dockets Management Branch
(HFA-305), Food and Drug
Administration, rm. 1-23, 12420
Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:
Mitchell Cheeseman, Center for Food
Safety and Applied Nutrition (HFS-
216), Food and Drug Administration,
200 C St. SW., Washington, DC 20204,
202-254-9511.

SUPPLEMENTARY INFORMATION: Under the
Federal Food, Drug, and Cosmetic Act
(sec. 409(b)(5) (21 U.S.C. 348(b)(5))),
notice is given that a food additive
petition (FAP 3B4383) has been filed by
BASF Corp., 8 Campus Dr., Parsippany,
NJ 07054. The petition proposes to
amend the food additive regulations to

provide for the safe use of 4,5,6,7-
tetrachloro-2-[2-(4,5,6,7-tetrachloro-2,3-
dihydro-1,3-dioxo-1H-inden-2-yl)-8-
quinolinyl]-1H-isoindole-1,3(2H)-dione
(C.I. Pigment Yellow 138, CAS Registry
No. 30125-47-4), as a colorant in all
food-contact polymers.

The potential environmental impact
of this action is being reviewed. To
encourage public participation
consistent with regulations promulgated
under the National Environmental
Policy Act (40 CFR 1501.4 (b)), the
agency is placing the environmental
assessment submitted with the petition
that is the subject of this notice on
public display at the Dockets
Management Branch (address above) for
public review and comment. Interested
persons may, on or before September 17,
1993, submit to the Dockets
Management Branch (address above)
written comments. Two copies of any
comments are to be submitted, except
that individuals may submit one copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the office
above between 9 a.m. and 4 p.m.,
Monday through Friday. FDA will also
place on public display any
amendments to, or comments on, the
petitioner's environmental assessment
without further announcement in the
Federal Register. If, based on its review,
the agency finds that an environmental
impact statement is not required and
this petition results in a regulation, the
notice of availability of the agency's
finding of no significant impact and the
evidence supporting that finding will be
published with the regulation in the
Federal Register in accordance with 21
CFR 25.40(c).

Dated: August 9, 1993.

Fred R. Shank,

*Director, Center for Food Safety and Applied
Nutrition.*

[FR Doc. 93-19892 Filed 8-17-93; 8:45 am]

BILLING CODE 4160-01-F

Clinical Studies of Safety and Effectiveness of Orphan Products; Availability of Grants; Establishment of Interested Parties List

AGENCY: Food and Drug Administration,
HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing
that it will publish a request for
applications (RFA) notice announcing
the anticipated availability of funds for
fiscal year (FY) 1994 for awarding grants
to support clinical trials on the safety

and effectiveness of orphan products
(i.e., those for diseases and conditions
affecting a U.S. population of less than
200,000, or those for which there is no
reasonable expectation of cost recovery).
Potential applicants interested in having
their names placed on a mailing list to
receive the FY 94 RFA should write or
call the Office of Orphan Products
Development (OPD).

ADDRESSES: Submit written requests to
be placed on the mailing list to Carol A.
Wetmore, Office of Orphan Products
Development (HF-35), Food and Drug
Administration, 5600 Fishers Lane, rm.
8-73, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:
Carol A. Wetmore or Patricia R. Robuck
(address above), 301-443-4903.

SUPPLEMENTARY INFORMATION:
Contingent on the availability of FY
1994 funds, in September 1993, FDA
plans to publish in the **Federal Register**
a notice announcing that it intends to
award approximately \$9.1 million for 25
to 30 new grants and continuations.
FDA advises that potential applicants
interested in having their names placed
on a mailing list to receive the FY 94
RFA write or call OPD (address above).

One established requirement for all
studies submitted pursuant to an OPD-
funded program, including studies for
products already approved, is that they
must be conducted under an
investigational new drug application
(IND) or an investigational device
exemption (IDE). The IND/IDE number
will be required to appear on the face
page of the application with the title of
the project. Other proposed submission
requirements are: Evidence of product
availability, evidence of patient
availability, and a well-supported
explanation as to why the product is
appropriate for an OPD grant.

Dated: August 11, 1993.

Michael R. Taylor,

Deputy Commissioner for Policy.

[FR Doc. 93-19891 Filed 8-17-93; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health,
HHS.

ACTION: Notice.

The inventions listed below are
owned by agencies of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of federally

funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated Licensing Specialist at the Office of Technology Transfer, National Institutes of Health, Box OTT, Bethesda, Maryland 20892 (telephone

301/496-7735; fax 301/402-0220). A signed Confidentiality Agreement will be required to receive copies of the patent applications. Issued patents may be obtained from the Commissioner of Patents, U.S. Patent and Trademark Office, Washington, DC 20231.

- 06/693,866 Cloning and Expression of HTLV-III DNA [encoding immunoreactive polypeptides useful in assays for detecting HTLV-III. Licensing Specialist: Steven M. Ferguson.
- 07/057,183 Human Immunodeficiency Virus Specific Proteolytic Enzyme and a Method for Its Synthesis and Renaturation (see also 07/201,654). Licensing Specialist: Steven M. Ferguson.
- 07/172,152 [Recombinant] Trans-Activating Factor of HTLV-III/LAV [useful for turning on the LTR promoter for construction of high efficiency expression systems]. Licensing Specialist: Steven M. Ferguson.
- 07/201,654 Human Immunodeficiency Virus Specific Proteolytic Enzyme and a method for Its Synthesis and Renaturation (see also 07/057,183). Licensing Specialist: Steven M. Ferguson.
- 07/202,508 Method of Treating AIDS, ARC or Lymphadenopathy Syndroms with Poly-ICLC [a synthetic double-stranded RNA complex] Alone or in Combination with AZT. Licensing Specialist: Steven M. Ferguson.
- 07/270,865 Quantitative, Syncytium-Forming Microassay for the Detection of HIV Neutralizing Antibody. Licensing Specialist: Steven M. Ferguson.
- 07/286,977 2,3 Epoxy Alcohols, Acids and Derivatives as Anti-Retroviral Chemotherapeutic Agents (U.S. Patent No. 5,190,969). Licensing Specialist: Steven M. Ferguson.
- 07/323,778 Rabbit Model for Diagnosing and Testing Vaccines or Therapeutic Agents Against AIDS (U.S. Patent No.5,183,949). Licensing Specialist: Steven M. Ferguson.
- 07/334,089 Chemotherapeutic Composition for AIDS [using inhibitors of nucleoside and nucleobase transport such as dipyridamole]. Licensing Specialist: Steven M. Ferguson.
- 07/401,411 Immunodominant Sites of HTLV-1 Envelope Protein [useful as immunogenic peptides for vaccine or diagnostic use]. Licensing Specialist: Steven M. Ferguson.
- 07/429,287 Construction of Non-Infectious Retroviral Mutants Deficient in Viral RNA. Licensing Specialist: Steven M. Ferguson.
- 07/454,827 Synthetic Peptides as Modulators of Functional Responses of Intact Cells [synthetic peptides as pharmacological agents, effectively inhibit cellular functions at the cellular molecular level in intact cells]. Licensing Specialist: Carl C. Floyd.
- 07/478,081 Method for Detection of Human Immunodeficiency Virus and Cell Lines Useful Therefor. Licensing Specialist: Steven M. Ferguson.
- 07/535,407 [Diagnostic] Method for Detecting Immune Dysfunction in Asymptomatic AIDS Patients and [also useful] for Predicting Organ Transplant Rejection. Licensing Specialist: Steven M. Ferguson.
- 07/594,156 A Plant Protein Useful for Treating Tumors and HIV Infections. Licensing Specialist: Steven M. Ferguson.
- 07/703,118 Method for Preventing Integration of Retroviral DNA into Host DNA. Licensing Specialist: Mark D. Hankins.
- 07/716,571 [Novel compound useful for stimulating the] Growth of Kaposi's Sarcoma Cells in Tissue Culture. Licensing Specialist: Steven M. Ferguson.
- 07/742,750 CD4+, Latently HIV-1-Infected Hematopoietic Progenitor Cells [that mimic the physiologic HIV-1 latency in the body]. Licensing Specialist: Steven M. Ferguson.
- 07/749,541 Anti-HIV Proteins GAP 31, DAP 30 and DAP 32, DNA Coding Therefor and Therapeutic Uses Thereof. Licensing Specialist: Steven M. Ferguson.
- 07/751,998 Multideterminant Peptide Antigens that Stimulate Helper T Lymphocytes Response to HIV in a Range of Human Subjects. Licensing Specialist: Steven M. Ferguson.
- 07/754,987 Method of Detecting Infectious HIV Strains [using CD4 expressing HeLa T4 cells with an inducible β -galactosidase gene]. Licensing Specialist: Steven M. Ferguson.
- 07/760,530 Method to Induce Cytotoxic T Lymphocytes Specific for a Broad Array of HIV-1 Isolates Using Hybrid Synthetic Peptides. Licensing Specialist: Steven M. Ferguson.
- 07/774,402 Reagents for the Detection and Differentiation of SIV and HIV Groups of Viruses. Licensing Specialist: Steven M. Ferguson.
- 07/811,896 Acquired Immune Deficiency Syndrome (AIDS) Viral Envelope Protein and Methods of Testing for Aids. Licensing Specialist: Steven M. Ferguson.
- 07/827,877 Novel Plasmid (pJL6) [that produces large amounts of the protein coded by the exogenous gene]. Licensing Specialist: Carl C. Floyd.
- 07/832,236 Method of Inhibiting HIV Protease. Licensing Specialist: Steven M. Ferguson.
- 07/847,311 Potent Peptide for Stimulation of Cytotoxic T Lymphocytes Specific for the HIV-1 Envelope. Licensing Specialist: Steven M. Ferguson.
- 07/847,744 Method of Modulating CD4-MHC Class II Interaction and Compounds Therefore. Licensing Specialist: Steven M. Ferguson.
- 07/861,249 Calanolides, Novel Antiviral Compounds Compositions and Uses Thereof. Licensing Specialist: Steven M. Ferguson.
- 07/861,938 Therapeutic Use of Restriction Enzymes Against Viruses, Including HIV. Licensing Specialist: Steven M. Ferguson.
- 07/870,547 Vectors for Ligation-Independent Cloning and Methods for Using Same. Licensing Specialist: Carl C. Floyd.
- 07/873,840 Aerosolization of Protein Therapeutic Agent. Licensing Specialist: Girish Barua.
- 07/882,078 Test of HIV-Specific T Lymphocyte Function that Detects Exposure to HIV Antigens and Possibly Early HIV Infection. Licensing Specialist: Steven M. Ferguson.
- 07/882,646 Dynamically Stable Associative Learning Neural Network System. Licensing Specialist: John Fahner-Vihtelic.
- 07/903,253 Methods for the Treatment of HIV [using a platelet activating factor (PAF) antagonist]. Licensing Specialist: Steven M. Ferguson.
- 07/906,716 Method for Viral-Proofing a Protective Barrier. Licensing Specialist: John Fahner-Vihtelic.
- 07/915,581 Apparatus and Method for Testing Condoms as Barriers to Virus Penetration. Licensing Specialist: John Fahner-Vihtelic.
- 07/917,213 Inhibition of Retroviral Expression by Interferon-Induced Cellular Genes and Proteins. Licensing Specialist: Steven M. Ferguson.
- 07/920,130 Amino Acid Sequencing Peptides and Methods for Their Use. Licensing Specialist: Carl C. Floyd.
- 07/921,992 DNA Segment Encoding a Natural Killer Cell Receptor. Licensing Specialist: Marjorie D. Hunter.

- 07/929,630 The Use of CD4+ Plasma Membrane Vesicles (CD4PMV) as a Therapeutic Agent for AIDS. Licensing Specialist: Steven M. Ferguson.
- 07/930,315 Pharmaceutical Compositions Containing AZO Dye Derivatives and Method of Using Same. Licensing Specialist: Steven M. Ferguson.
- 07/937,097 Ear Based Hearing Protector/Communication System. Licensing Specialist: John Fahner-Vihtelic.
- 07/943,246 Expression of Active Human Protein C in Mammary Tissue of Transgenic Animals Using a Long WAP Promoter. Licensing Specialist: Carl C. Floyd.
- 07/946,613 Method for Concentrating a Solute by Countercurrent Chromatography. Licensing Specialist: John Fahner-Vihtelic.
- 07/950,020 [Efficient alternative] Methods for Detection of Mycoplasmas [in mammalian cell cultures]. Licensing Specialist: Carl C. Floyd.
- 07/952,277 Eleven Highly Informative Microsatellite Repeat Polymorphic DNA Markers. Licensing Specialist: Carl C. Floyd.
- 07/952,800 New Member of the Nuclear Hormone Receptor Superfamily and a cDNA Clone Thereof. Licensing Specialist: Carl C. Floyd.
- 07/956,870 Carriers for Self-Administration of Lyophilized Medicament to Animals [An animal food product for self-administration of medication to animals]. Licensing Specialist: Carl C. Floyd.
- 07/963,328 Supercoiled Minicircle DNA as a Unitary Promoter Vector. Licensing Specialist: Carl C. Floyd.
- 07/965,544 The Use of Monoclonal Antibodies That Define Oncostatin M to Inhibit Growth of Kaposi's Sarcoma. Licensing Specialist: Carl C. Floyd.
- 07/966,244 Improved Multi-Unit Analyser. Licensing Specialist: John Fahner-Vihtelic.
- 07/967,658 An Immunological Detection Assay for Human Immunodeficiency Virus (HIV) Based on the HIV Nucleocapsid Protein, p7. Licensing Specialist: Steven M. Ferguson.
- 07/971,093 A Method of Generation of Nested Deletions [Randomized-primed/anchored polymerase chain reaction, a novel method to generate clones from nested deletions]. Licensing Specialist: Carl C. Floyd.
- 07/974,055 Detection of Isocyanates in Air by Use of Polar Organic Solvents. Licensing Specialist: John Fahner-Vihtelic.
- 07/998,231 Compositions and Methods for Inhibiting Deoxyhypusine Synthase and the Growth of Cells. Licensing Specialist: Marjorie D. Hunter.
- 08/010,695 Multifinger Topocatheter Tip for Multilumen Catheter for Angioplasty and Manipulation. Licensing Specialist: John Fahner-Vihtelic.
- 08/010,696 Prosthetic Ligament Abrasion Tester. Licensing Specialist: John Fahner-Vihtelic.
- 08/011,183 Antiviral Naphthoquinone Compounds, Compositions and Uses Thereof. Licensing Specialist: Steven M. Ferguson.
- 08/012,988 Complementary DNA Encoding the Macrophage Inflammatory Protein-1 (MIP-1)/Rantes Receptor. Licensing Specialist: Carl C. Floyd.
- 08/015,983 Method and Apparatus for Localization and Spectroscopy of Objects Using Optical Frequency Modulation of Diffusive Waves. Licensing Specialist: John Fahner-Vihtelic.
- 08/017,062 Recombinant Protein Bioreactor System. Licensing Specialist: John Fahner-Vihtelic.
- 08/020,462 Screening Test that Identifies Individuals at Increased Risk for the Development of Lymphoid Leukemia and Lymphoma. Licensing Specialist: Marjorie D. Hunter.
- 08/020,952 Oxy-Hydrogen Propelled Torpedo for Introducing Angioplasty Guide Wire. Licensing Specialist: John Fahner-Vihtelic.
- 08/021,767 Light Sensor for Photo-Dynamic Therapy. Licensing Specialist: John Fahner-Vihtelic.
- 08/025,336 Human Liver Epithelial Cell Line and Culture Media Therefor. Licensing Specialist: Steven M. Ferguson.
- 08/025,471 Monoterpenes, Sesquiterpenes and Diterpenes as Cancer Therapy. Licensing Specialist: Marjorie D. Hunter.
- 08/026,939 pH-Zone Refining Countercurrent Chromatography. Licensing Specialist: John Fahner-Vihtelic.
- 08/027,111 Improved Cross-Axis Coil Planet Centrifuge for Separation of Biopolymers. Licensing Specialist: John Fahner-Vihtelic.
- 08/029,917 cDNA Encoding the Rat D₂ Dopamine Receptor Linked to Adenylyl Cyclase Activation and Expression of the Receptor Protein in Plasmid-Transfected Cell Lines. Licensing Specialist: Arthur J. Cohn.
- 08/038,198 Method of Exciting Laser Action and Delivering Laser Energy for Medical and Scientific Application. Licensing Specialist: John Fahner-Vihtelic.
- 08/038,344 Cystathionase and Derivatives Thereof. Licensing Specialist: Marjorie D. Hunter.
- 08/039,613 Dust Control Plenum for a Hand Sander. Licensing Specialist: John Fahner-Vihtelic.
- E-030-92/1 Handheld Spirometry with Improved Accuracy. Licensing Specialist: John Fahner-Vihtelic.
- E-085-92/1 An Anti HIV Protein, TAP 29 from Trichosanthes, DNA Coding Therefor and Therapeutic Uses Thereof. Licensing Specialist: Steven M. Ferguson.

Opportunity for a License: Assay for Inhibitors of HIV DNA Integration

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health desires to license a novel *in vitro* assay system for identifying potential anti-retroviral (anti-HIV) drugs that target HIV integration and the HIV integrase protein. The lack of therapeutics in clinical development which affect this step in the HIV life cycle was noted recently in *Science*, Vol. 260, p. 1257 (May 28, 1993). This particular assay can be useful for determining whether viral integration into a host or target DNA is achieved or

alternatively, whether integration is inhibited by a test drug. The assay uses HIV and MoLV recombinant integrase (IN) protein and synthetic oligonucleotides as substrates. Each step of the assay can be carried out in microtiter well plates enabling the easily automated simultaneous processing of large numbers of samples.

This new assay is believed to have significant advantages over current integration assays that are time consuming and utilize cells infected with HIV. For a more in-depth discussion on this assay see: Craigie, et al., *Nucleic Acids Research*, Vol. 19, p. 2729, (March, 1991).

NIH is the assignee of the patent rights for this technology covered by U.S. Patent Application 08/038,182

(FWC of 07/572,186) and developed by Dr. Robert Craigie, Dr. Frederic Bushman and Dr. Kiyoshi Mizuuchi of the National Institute of Diabetes, Digestive and Kidney Diseases.

ADDRESSES: Licensing information and a copy of the U.S. patent application may be obtained by contacting Steven M. Ferguson, Technology Licensing Specialist, National Institutes of Health, Office of Technology Transfer, Box OTT, Bethesda, Maryland 20892 (telephone 301/496-7735; fax 301/402-0220). A signed confidentiality agreement will be required to receive copies of the patent applications.

Dated: August 10, 1993.

Reid G. Adler,

Director, Office of Technology Transfer.

[FR Doc. 93-19903 Filed 8-17-93; 8:45 am]

BILLING CODE 4140-01-M

**DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT**

**Office of the Assistant Secretary for
Housing—Federal Housing
Commissioner**

[Docket No. N-93-3590; FR-3409-N-03 and
N-93-3591; FR-3408-N-03]

**Fund Availability for Supportive
Housing for Persons with Disabilities
and Supportive Housing for the
Elderly; Extensions for Cleveland Field
Office and New York Regional Office**

AGENCY: Office of the Assistant
Secretary for Housing—Federal Housing
Commissioner, HUD.

ACTION: Notice of limited deadline
extension.

SUMMARY: This Notice announces an extension of the application deadline for capital advances for the Supportive Housing for Persons With Disabilities and Supportive Housing for the Elderly programs for those applicants whose applications were submitted late to the Cleveland Field Office and the New York Regional Office as a result of conflicting instructions issued by those offices.

DATES: For affected applicants, the deadline date is being extended to August 23, 1993.

FOR FURTHER INFORMATION CONTACT: Stephen J. Havens, Assisted Elderly and Handicapped Housing Division, Department of Housing and Urban Development, room 6112, 451 Seventh St. SW., Washington, DC 20410, telephone 202-708-2730. To provide service for persons who are hearing- or speech-impaired, this number may be reached via TDD by dialing the Federal Information Relay Service on 1-800-877-TDDY, 1-800-877-8339, or 202-708-9300. (Telephone numbers, other than "800" TDD numbers, are not toll free.)

SUPPLEMENTARY INFORMATION: On May 5, 1993, HUD published Notices of Fund Availability for the Supportive Housing for Persons with Disabilities (58 FR 26824) and Supportive Housing for the Elderly (58 FR 26843) programs. In these NOFAs, HUD established an application deadline of 4 p.m. local time on July 8, 1993 in each HUD field office. Late applications were received in the Cleveland Field Office and the New

York Regional Office because of conflicting information given to potential applicants on the time of the deadline, erroneously stated at close of business local time (4:40 p.m. in Cleveland and 5 p.m. in New York).

In today's Notice, HUD is extending the application deadline only for those sponsors whose applications were rejected or not accepted as a result of reliance upon the later submission time in the Cleveland Field Office and New York Regional Office. For those applicants who qualify, the application deadline is extended until 4 p.m. local time on August 23, 1993.

An applicant may qualify for extension of the application deadline for capital advances under the Supportive Housing for Persons With Disabilities and Supportive Housing for the Elderly programs if:

(1) The applicant certifies that it relied upon the deadline times established by the Cleveland Field Office and the New York Regional Office rather than the published NOFA deadline; and

(2) The applicant certifies and the HUD office determines that an attempt was made to deliver or the applications were actually delivered to the Cleveland and New York offices prior to their stated deadlines (4:40 p.m. in Cleveland and 5 p.m. in New York).

If HUD approves the certification, the application will be accepted for review.

A qualified applicant may resubmit its previously submitted application as long as the application is received by the Cleveland or New York office by the extended deadline above. All submission requirements published in the May 5, 1993 NOFAs other than the date by which such applications must be received remain unaffected by this Notice.

Dated: August 12, 1993.

Nicolas P. Retsinas,

Assistant Secretary for Housing—Federal
Housing Commissioner.

[FR Doc. 93-19899 Filed 8-17-93; 8:45 am]

BILLING CODE 4210-27-M

**Office of the Assistant Secretary for
Housing—Federal Housing
Commissioner**

[Docket No. N-93-3655; FR-3559-N-01]

**Mortgagee Review Board
Administrative Actions**

AGENCY: Office of the Assistant
Secretary for Housing—Federal Housing
Commissioner, HUD.

ACTION: Notice.

SUMMARY: In compliance with section 202(c)(5) of the National Housing Act, notice is hereby given of the cause and description of administrative actions taken by HUD's Mortgagee Review Board against HUD-approved mortgagees.

DATES: August 18, 1993.

FOR FURTHER INFORMATION CONTACT: William Heyman, Director, Office of Lender Activities and Land Sales Registration, 451 Seventh Street SW., Washington, DC 20410; telephone (202) 708-1824; TDD number (202) 708-4594. (These are not toll-free numbers.)

SUPPLEMENTARY INFORMATION: Section 202(c)(5) of the National Housing Act (added by section 142 of the Department of Housing and Urban Development Reform Act of 1989 (Pub. L. 101-235, approved December 15, 1989)) requires that HUD "publish in the Federal Register a description of and the cause for administrative action against a HUD-approved mortgagee" by the Department's Mortgagee Review Board. In compliance with the requirements of section 202(c)(5), notice is hereby given of administrative actions that have been taken by the Mortgagee Review Board from April 1, 1993 through June 30, 1993.

I. Mortgagees cited for failure to comply with HUD-FHA reporting requirements under the Home Mortgage Disclosure Act (HMDA) and/or Quality Control Plan requirements for the origination of HUD-FHA insured mortgages.

Action: Letters of Reprimand

Cause: HUD monitoring reviews that disclosed noncompliance by the following mortgagees with the Department's reporting requirements under HMDA and/or failure to comply with HUD-FHA requirements for maintaining a Quality Control Plan.

Mortgagees issued a Letter of Reprimand for failure to meet HMDA reporting requirements and to maintain an adequate loan origination Quality Control Plan:

Westminster Mortgage Company, Houston, Texas; First American Mortgage of Texas, Austin, Texas; Aviles & Associates, Inc., Tampa, Florida; Suburban Financial Corporation, Leawood, Kansas; Allied Mortgage Capital Corporation, Houston, Texas; United Security Financial, Salt Lake City, Utah; First Choice Mortgage Corporation, Independence, Ohio; Johnston & Nelson, Inc., Phoenix, Arizona; Columbia Mortgage Incorporated, Phoenix, Arizona; Mortgage Center, Inc., Houston, Texas;